Biomind Begins Clinical Trial For Inhaled DMT Analog Substance To Treat Depression

Biomind Labs (OTCQB:BMNDF) has begun administering its proprietary second-generation psychedelic, BMND01, in a Phase 1/2a clinical trial for treatment-resistant depression (TRD).

The company administered the first subject with the DMT analog to evaluate the safety, pharmacokinetics, behavioral and brain effects of the molecule through inhalation. The team in charge of the study is led by Dr. Dráulio Araújo, Biomind’s scientific and clinical advisor.

“An inhaled formulation …

Full story available on Benzinga.com

More Biomind Begins Clinical Trial For Inhaled DMT Analog Substance To Treat Depression